November 20, 2022
3 min watch
Williams reports serving on an independent data monitoring committee for GlaxoSmithKline and a scientific advisory board for Quidel.
NEW YORK — In this video filmed at the Infectious Diseases in Children Symposium, John V. Williams, MD, describes multiple interventions in development against respiratory syncytial virus, which is currently surging in the United States.
According to Williams, these include newer, longer lasting monoclonal antibodies and multiple vaccine candidates in late-stage development.
Williams, who is the division chief of pediatric infectious diseases at the UPMC Children’s Hospital of Pittsburgh and director of the Institute for Infection, Inflammation and Immunity in Children (i4Kids), said it is “likely” there will be licensed RSV vaccines for older adults and pregnant people “within the next year or so.”
“This is really exciting for us as pediatricians because we have really lacked tools against RSV for far too long,” Williams said.
Williams JV. Keynote presentation: Preview of coming attractions: Preventions for RSV. Presented at: Infectious Diseases in Children Symposium; Nov. 19-20, 2022; New York (hybrid meeting).